Evidence map›Paper›PMID 31853808›Full record

ArticleLasers in medical science2020

Normal-subtracted preprocessing of Raman spectra aiming to discriminate skin actinic keratosis and neoplasias from benign lesions and normal skin tissues.

Landulfo Silveira, Carlos Augusto Pasqualucci, Benito Bodanese, Marcos Tadeu Tavares Pacheco, Renato Amaro Zângaro

Abstract read
PubMed Publisher
In one paragraph

Article in Lasers in medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Noninvasive Technologies for the Diagnosis of Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.JID innovations : skin science from molecules to population health · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Landulfo SilveiraCenter for Innovation, Technology and Education - CITE, Universidade Anhembi Morumbi - UAM, Estr. Dr. Altino Bondensan, 500, Sao Jose dos Campos, SP, 12247-016, Brazil. landulfo.silveira@gmail.com.ORCID http://orcid.org/0000-0002-6616-3334
Carlos Augusto PasqualucciDepartment of Cardiovascular Pathology, Faculty of Medicine, Universidade de São Paulo - USP, Av. Dr. Arnaldo, 455 - Cerqueira César, Sao Paulo, SP, 01246-903, Brazil.
Benito BodaneseDepartment of Oncology, Hospital Regional do Oeste - HRO, R. Florianópolis, 1448-E, Chapecó, SC, 89812-021, Brazil.
Marcos Tadeu Tavares PachecoCenter for Innovation, Technology and Education - CITE, Universidade Anhembi Morumbi - UAM, Estr. Dr. Altino Bondensan, 500, Sao Jose dos Campos, SP, 12247-016, Brazil.
Renato Amaro ZângaroCenter for Innovation, Technology and Education - CITE, Universidade Anhembi Morumbi - UAM, Estr. Dr. Altino Bondensan, 500, Sao Jose dos Campos, SP, 12247-016, Brazil.
Anhembi Morumbi University · BRInstituto Florestal · BRUniversidade de São Paulo · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 301325/2016-2Conselho Nacional de Desenvolvimento Científico e Tecnológico 306344/2017-3Fundação de Amparo à Pesquisa do Estado de São Paulo 2009/01788-5
6 · The paper itself

Abstract

The differences in the biochemistry of normal and cancerous tissue could be better exploited by Raman spectroscopy when the spectral information from normal tissue is subtracted from the abnormal tissues. In this study, we evaluated the use of the normal-subtracted spectra to evidence the biochemical differences in the pre-cancerous and cancerous skin tissues compared with normal skin, and to discriminate the groups with altered tissues with respect to the normal sites. Raman spectra from skin tissues [normal (Normal), benign (dermatitis-BEN), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and actinic keratosis (KER)] were obtained in vivo (Silveira et al., 2015, doi: https://doi.org/10.1002/lsm.22318) and used to develop the spectral model. The mean spectrum of the normal sites (circumjacent to each lesion) from each subject was calculated and subtracted from each individual spectrum of that particular subject independently of the group (Normal, BEN, BCC, SCC, KERAT). The mean spectra of each altered group and the mean spectra of the differences were firstly evaluated in terms of biochemical contribution or differentiation comparing the normal site. Then, the normal-subtracted spectra were submitted to discriminant models based on partial least squares and principal components regression (PLS-DA and PCR-DA), and the discrimination were compared with the model using non-subtracted spectra. Results showed that the peaks of nucleic acids, lipids (triolein) and proteins (elastin and collagens I, III, and IV) were significantly different in the lesions, higher for the pre- and neoplastic lesions compared with normal and benign. The PLS-DA showed that the groups could be discriminated with 90.3% accuracy when the mean-subtracted spectra were used, contrasting with 75.1% accuracy when the non-subtracted spectra were used. Also, when discriminating non-neoplastic tissue (Normal + BEN) from pre- and neoplastic sites (BCC + SCC + KERAT), the accuracy increases to 92.5% for the normal-subtracted compared with 85.3% for the non-subtracted. The subtraction of the mean normal spectrum from the subject obtained circumjacent to each lesion could significantly increase the diagnostic capability of the Raman-based discrimination algorithm.

Indexed as

AlgorithmsSpectrum Analysis, RamanBasal Cell CarcinomaCarcinoma, Squamous CellDiscriminant AnalysisHumansKeratosis, ActinicLeast-Squares AnalysisPrincipal Component AnalysisSkinSkin NeoplasmsIn vivo diagnosisRaman spectroscopySkin neoplasiaSpectral model

Identifiers

PMID31853808
OpenAlexW2996342775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.